[EN] TRIAZOLE, OXADIAZOLE AND THIADIAZOLE DERIVATIVE AS PPAR MODULATORS FOR THE TREATMENT OF DIABETES<br/>[FR] DERIVE DE TRIAZOLE, OXADIAZOLE ET THIADIAZOLE EN TANT QUE MODULATEURS DE PPAR POUR LE TRAITEMENT DU DIABETE
申请人:LILLY CO ELI
公开号:WO2005065683A1
公开(公告)日:2005-07-21
The present invention is directed to compounds represented by the following structural formula, Formula (I): wherein: (a) X is selected from the group consisting of a single bond, O, S, S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, S, NH and a single bond; (d) W is N, O or S; (e) E is C(R3)(R4)A or A and wherein; (f) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamide, sulfonamide and acylsufonamide. The other substituents are defined in the claims; the compounds are modulators of peroxisome proleferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders.
本发明涉及由以下结构式表示的化合物,结构式(I):其中:(a)X选自单键、O、S、S(O)2和N组成的群体;(b)U是脂肪链连接物;(c)Y选自O、C、S、NH和单键组成的群体;(d)W为N、O或S;(e)E为C(R3)(R4)A或A,其中;(f)A选自羧基、四唑基、C1-C6烷基腈、羧酰胺、磺酰胺和酰基磺酰胺组成的群体。其他取代基在权利要求中定义;这些化合物是过氧化物酶增殖物活化受体(PPARs)的调节剂,对糖尿病和其他代谢性疾病的治疗有用。